Carfilzomib in combination with lenalidomide and dexamethasone – feasibility and efficacy of a new consolidation regimen in inducing and/or re-inducing minimal residual disease negativity in multiple myeloma patients after a first autologous stem cell transplant. A prospective, multicenter, interventional, open label, phase II Trial.

Trial Profile

Carfilzomib in combination with lenalidomide and dexamethasone – feasibility and efficacy of a new consolidation regimen in inducing and/or re-inducing minimal residual disease negativity in multiple myeloma patients after a first autologous stem cell transplant. A prospective, multicenter, interventional, open label, phase II Trial.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2018

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top